This is a working overview of Mod GRF(1-29), written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-01. Anything still debated is marked as such rather than presented as settled.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
In structural biology, a protein subunit is a polypeptide chain or single protein molecule that assembles (or "coassembles") with others to form a protein complex. Large assemblies of proteins such as viruses often use a small number of types of protein subunits as building blocks. A subunit is often named with a Greek or Roman letter, and the numbers of this type of subunit in a protein is indicated by a subscript. For example, ATP synthase has a type of subunit called α. Three of these are present in the ATP synthase molecule, leading to the designation α3. Larger groups of subunits can also be specified, like α3β3-hexamer and c-ring. Naturally occurring proteins that have a relatively small number of subunits are referred to as oligomeric. For example, hemoglobin is a symmetrical arrangement of two identical α-globin subunits and two identical β-globin subunits. Longer multimeric proteins such as microtubules and other cytoskeleton proteins may consist of very large numbers of subunits. For example, dynein is a multimeric protein complex involving two heavy chains (DHCs), two intermediate chains (ICs), two light-intermediate chains (LICs) and several light chains (LCs). The subunits of a protein complex may be identical, homologous or totally dissimilar and dedicated to disparate tasks. In some protein assemblies, one subunit may be a "catalytic subunit" that enzymatically catalyzes a reaction, whereas a "regulatory subunit" will facilitate or inhibit the activity.
A light-emitting diode (LED) is an electronic component that uses a semiconductor to emit light when current flows through it. Electrons in the semiconductor recombine with electron holes, thereby releasing energy in the form of photons. The color of the light (corresponding to the energy of the photons) is determined by the energy required for electrons to cross the band gap of the semiconductor. White light is obtained by using multiple semiconductors or a layer of light-emitting phosphor on the semiconductor device. Appearing as practical electronic components in 1962, the earliest LEDs emitted low-intensity infrared (IR) light. Infrared LEDs are used in remote-control circuits, such as those used with a wide variety of consumer electronics. The first visible-light LEDs were of low intensity and limited to red. Early LEDs were often used as indicator lamps, replacing small incandescent bulbs, and in seven-segment displays. Later developments produced LEDs available in visible, ultraviolet (UV), and infrared wavelengths with high, low, or intermediate light output; for instance, white LEDs suitable for room and outdoor lighting. LEDs have also given rise to new types of displays and sensors, while their high switching rates have uses in advanced communications technology. LEDs have been used in diverse applications such as aviation lighting, fairy lights, strip lights, automotive headlamps, advertising, stage lighting, general lighting, traffic signals, camera flashes, lighted wallpaper, horticultural grow lights, and medical devices.
=== 23 July === The Russian military claimed to have taken the village of Ivano-Daryivka, 30 kilometers northeast of Bakhmut, although the village had been under Russian occupation since 17 July. In Russia, the governor of Krasnodar Krai claimed that a Ukrainian drone attack on a ferry in Port Kavkaz killed one, wounded one and started a fire on board the vessel. The Russian defence ministry claimed that 21 drones had been shot down over the Black Sea and in Crimea. The Ukrainian military claimed to have shot down a Russian Su-25 fighter jet over Donetsk Oblast. A Ukrainian HIMARS strike hit a Russian 1K148 Yastreb-AV counter-battery radar in Zuhres, Donetsk Oblast. The SBU arrested a former host and journalist on suspicion of inciting armed resistance against mobilisation into the Ukrainian military on social media. EU foreign policy chief Josep Borrell stripped Hungary of its right to host a meeting of EU foreign and defence ministers scheduled on 28–30 August due to Prime Minister Viktor Orban's meeting with Putin and his accusations against the EU having a "pro-war policy". Ukraine's Tavria operational-strategic group claimed that there were 90,000 Russian troops in Zaporizhzhia Oblast, and that 2,000 of them had joined in recent weeks.
Sources: en.wikipedia.org
=== Europe === Dihydromorphine is regulated in the same fashion as morphine in Germany under the BtMG, Austrian SMG, and Swiss BtMG, where it is still used as an analgesic. The drug was invented in Germany in 1900 and marketed shortly thereafter. It is often used in Patient Controlled Analgesia units.
== Life and career == Eric M. Verdin was born in Belgium. He has a BS in Medical Sciences and doctorate of medicine from the University of Liege. After graduating from university, Verdin trained at Harvard Medical School. In 1997, he joined the Gladstone Institute for Virology and Immunology, where he worked for twenty years. He ended his time there as associate director and senior investigator in the virology and immunology unit. He is also a professor of medicine at the University of California, San Francisco. He previously held faculty positions at the National Institutes of Health and at Picower Institute for Medical Research. He is on the scientific advisory board of Amazentis and previously served on the National Scientific Advisory Council of the American Federation for Aging Research. He was a consultant to Calico, an aging-research company founded by Google. He is an inventor on at least 15 published patents. Verdin recreationally races race cars and trains for mental and physical endurance in LMP, Formula Atlantic and Formula 1 cars.
=== Waffle and Steak === For years, Waffle House was known as "Waffle and Steak" in Indiana due to another chain of restaurants owning the rights to the Waffle House name in the state. The original Indiana Waffle House chain has started using the name "Sunshine Cafe". However, the d/b/a for "Sunshine Cafe" belongs to "Waffle House Greenwood Inc.", established in 1981. The oldest "Waffle House" entity listed with the Corporations office of the Indiana Secretary of State is "Waffle House of Bloomington, Indiana, Inc." established in 1967, and, like Waffle House Greenwood, it is still an active corporation. The Bloomington operation, the city's second oldest restaurant, closed in 2013, and was demolished to make way for an apartment complex. (Many of the Waffle House corporations in Indiana have been dissolved.) "Waffle House Inc." of Norcross, Georgia, registered with Indiana in 1974. In 2005, the Waffle and Steak restaurants all adopted the "Waffle House" moniker, bringing the entire chain under the name.
=== Occupation === Early forms of the receptor theory of pharmacology stated that a drug's effect is directly proportional to the number of receptors that are occupied. Furthermore, a drug effect ceases as a drug-receptor complex dissociates. Ariëns & Stephenson introduced the terms "affinity" & "efficacy" to describe the action of ligands bound to receptors.
Sources: en.wikipedia.org
Cells receive information from their neighbors through a class of proteins known as receptors. Receptors may bind with some molecules (ligands) or may interact with physical agents like light, mechanical temperature, pressure, etc. Reception occurs when the target cell (any cell with a receptor protein specific to the signal molecule) detects a signal, usually in the form of a small, water-soluble molecule, via binding to a receptor protein on the cell surface, or once inside the cell, the signaling molecule can bind to intracellular receptors, other elements, or stimulate enzyme activity (e.g. gasses), as in intracrine signaling. Signaling molecules interact with a target cell as a ligand to cell surface receptors, and/or by entering into the cell through its membrane or endocytosis for intracrine signaling. This generally results in the activation of second messengers, leading to various physiological effects. In many mammals, early embryo cells exchange signals with cells of the uterus. In the human gastrointestinal tract, bacteria exchange signals with each other and with human epithelial and immune system cells. For the yeast Saccharomyces cerevisiae during mating, some cells send a peptide signal (mating factor pheromones) into their environment. The mating factor peptide may bind to a cell surface receptor on other yeast cells and induce them to prepare for mating.
On March 11, 1997, National Semiconductor Corporation announced the US$550 million sale of a reconstituted Fairchild to the management of Fairchild with the backing of Sterling LLC, a unit of Citicorp Venture Capital. Fairchild carried with it what was mostly the Standard Products group previously segregated by Amelio. Incidentally, the effective price of acquisition of Cyrix was also US$550 million. On November 17, 1997, National Semiconductor and Cyrix announced the merger of the companies. Cyrix would become an autonomous wholly owned subsidiary. Halla had earlier emphasized that National was after the low-end CPU market as part of the system-on-a-chip pursuit and therefore would not place emphasis on Cyrix's current development of high-end 6x86MX design. However, Cyrix later announced that its merger with National Semiconductor would not change its development or marketing plans. The acquisition of an independent-minded Cyrix subsequently turned National Semiconductor from a collaborator into a competitor with Intel. National lost its business with Intel. Intel reinstated the relationship after the sale of Cyrix. The acquisition of Cyrix also carried with it a business obligation to use the IBM Microelectronics Division to fabricate the Cyrix chips, as well as technical constraint to do the same, while National Semiconductor had plans to transfer their fabrication to its South Portland fab. National incurred huge losses in its processor business and announced the sale of Cyrix to VIA in 1999.
=== Optical modulator === When the Fermi level of graphene is tuned, its optical absorption can be changed. In 2011, researchers reported the first graphene-based optical modulator. Operating at 1.2 GHz without a temperature controller, this modulator has a broad bandwidth (from 1.3 to 1.6 μm) and small footprint (~25 μm2). A Mach-Zehnder modulator based on a hybrid graphene-silicon waveguide has been demonstrated recently, which can process signals nearly chirp-free. An extinction up to 34.7 dB and a minimum chirp parameter of -0.006 are obtained. Its insertion loss is roughly -1.37 dB.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.